MAPKAPK2 (MK2)
Read More about this categoryShow Less
MAP kinase-activated protein kinase 2 (MAPKAPK2) is an enzyme that in humans is encoded by the MAPKAPK2 gene. MAPKAP kinase-2 (MK2) is originally identified by its phosphorylation of glycogen synthase at serine-7 and the corresponding serine in a peptide (GS peptide-1) modelled after the N-terminus of glycogen synthase.
MAPKAP kinase-2 is a novel protein kinase activated by mitogen-activated protein kinase. This MAP kinase activated protein kinase, termed MAPKAP kinase-2, is distinguished from S6 kinase-II (MAPKAP kinase-1) by its response to inhibitors, lack of phosphorylation of S6 peptides and amino acid sequence.
Products Related to MAPKAPK2 (MK2)(9)
- GC16723MK2 Inhibitor IVCAS: 1314118-94-9Purity: >98.50%
MK2 Inhibitor IV is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode.
- GC33142MK2-IN-1 (MK2 Inhibitor)CAS: 1314118-92-7Purity: >98%
MK2-IN-1 (MK2 Inhibitor) is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode.
- GC44211MK2 Inhibitor IIICAS: 1186648-22-5Purity: >95.00%
MK2 Inhibitor III (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM.
- GC63425ZunsemetinibCAS: 1640282-42-3Purity: ≥99.00%
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC11180 | CMPD-1 | 41179-33-3 | >99.00% | |
inhibitor of p38α-mediated MK2a phosphorylation | ||||
| GC14645 | PF-3644022 | 1276121-88-0 | >98.00% | |
Potent and Selective MK2 inhibitor | ||||
| GC16723 | MK2 Inhibitor IV | 1314118-94-9 | >98.50% | |
MK2 Inhibitor IV is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode. | ||||
| GC33142 | MK2-IN-1 (MK2 Inhibitor) | 1314118-92-7 | >98% | |
MK2-IN-1 (MK2 Inhibitor) is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode. | ||||
| GC44211 | MK2 Inhibitor III | 1186648-22-5 | >95.00% | |
MK2 Inhibitor III (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM. | ||||
| GC61819 | MK2-IN-3 | 724711-21-1 | >98.00% | |
MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. | ||||
| GC63425 | Zunsemetinib | 1640282-42-3 | ≥99.00% | |
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. | ||||
| GC63441 | CC-99677 | 1887069-10-4 | >98% | |
CC-99677 is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). | ||||
| GC64580 | MMI-0100 | 1039342-24-9 | >99.00% | |
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). | ||||